Arovella Therapeutics Limited (ASX:ALA)

Dr Duthy has over 18 years of direct financial markets experience and is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations firm specialising in the life sciences and technology sectors.

Passionate about creating life changing medications for the betterment of humankind, Dr Baker’s careers spans academic research, drug development and venture investing. His primary focus is to get medications into the hands of patients that need them.

Dr Stoner is a distinguished biopharma executive, who brings decades of international industry experience to her role, including senior roles in Clinical Development Operations at Merck Research Laboratories. Liz is an Executive Partner at MPM Capital.

Dedicating her career to the treatment of cancer, Dr Barton began her career as a clinical oncologist before moving into drug development in large pharmaceutical companies and more recently into biotechnology companies at the forefront of cancer treatment.

Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. He is currently the CEO and Managing Director of the ASX-listed company, Pharmaxis.